ACTRN12626001033336招募中2 期
A Phase II Double-Blinded, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of SIR4156 in Combination with Semaglutide on Total Body Fat Mass and Body Composition in Adults with Obesity
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 113
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 75 Years（—）
- 性别
- All
入选标准
- •Adults aged 18 to 75 years with obesity defined as body mass index greater than or equal to 30 kilograms per square meter, with stable body weight prior to screening, and able to comply with study procedures.
排除标准
- •Participants with diabetes mellitus, use of weight loss medications within a recent period prior to screening, significant cardiovascular, hepatic or renal disease, pregnancy or breastfeeding, or any condition that in the opinion of the investigator would make participation unsafe or interfere with study results.
研究者
相似试验
尚未招募
不适用
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) (J2S-MC-GZMT)Irritable Bowel Syndrome
ConstipationIrritable Bowel Syndrome ConstipationjRCT2031260143342
尚未招募
不适用
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) (J2S-MC-GZMS)Irritable Bowel Syndrome
DiarrheajRCT2031260148531
招募中
不适用
A Study of TAK-755 in Adults With Acute Ischemic StrokeAcute Ischemic StrokejRCT2071260013222
尚未招募
不适用
A Trial of NS-863 in Participants with Pulmonary Arterial Hypertension (PAH) (NS863A-P2-01)Pulmonary Arterial HypertensionjRCT203126022221
招募中
1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATX3042024-514744-91-00Betagenon AB, Betagenon AB40